慢性肾脏病进展的脂质组学特征:慢性肾功能不全队列研究
研究从慢性肾功能不全队列中选取79例6年内进展至终末期肾病的CKD 2-3期患者,按年龄、性别、种族和糖尿病频率匹配121例未进展者,对第1年样本行液相色谱-质谱脂质组学分析。发现甘油二酯和胆固醇酯丰度较低,而磷脂酸44:4和单酰甘油16:0显著较高;由甘油二酯和单酰甘油组成的多标志物面板加入基础模型后,预测进展的c统计量从0.83提高至0.92,并在测试集中验证。
要点
- 特定脂质面板可提升CKD进展预测,优于单独eGFR和UPCR。
- 进展者甘油二酯和胆固醇酯较低,磷脂酸44:4和单酰甘油16:0较高。
- 多标志物面板加入eGFR和UPCR后c统计量达0.92。
核心结论
- 特定脂质面板加入eGFR和UPCR基础模型后,可改善CKD进展预测。
研究设计与样本
- 来自慢性肾功能不全队列的病例对照研究,79例进展至ESKD者与121例未进展者按年龄、性别、种族和糖尿病频率匹配。
- 对第1年样本行液相色谱-质谱脂质组学分析,患者随机分为训练集和测试集。
主要发现
- 鉴定出510种脂质,训练集中前10种脂质在错误发现阈值0.058下重合。
- 进展者甘油二酯和胆固醇酯丰度较低,磷脂酸44:4和单酰甘油16:0显著较高。
- 由甘油二酯和单酰甘油组成的多标志物面板独立预测进展。
- 多标志物面板加入基础模型后c统计量为0.92(95%CI:0.88-0.97),基础模型为0.83(95%CI:0.76-0.90,P<0.01),并在测试集中验证。
临床怎么用
- 在eGFR和UPCR基础上,可考虑检测特定脂质面板以提升CKD进展风险预测。
局限性
- 研究为病例对照设计,样本量有限,需更大规模队列验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Human studies report conflicting results on the predictive power of serum lipids on progression of chronic kidney disease (CKD). We aimed to systematically identify the lipids that predict progression to end-stage kidney disease. METHODS: From the Chronic Renal Insufficiency Cohort, 79 patients with CKD stage 2 to 3 who progressed to ESKD over 6 years of follow up were selected and frequency-matched by age, sex, race, and diabetes with 121 non-progressors with less than 25% decline in estimated glomerular filtration rate (eGFR) during the follow up. The patients were randomly divided into Training and Test sets. We applied liquid chromatography-mass spectrometry-based lipidomics on visit year 1 samples. RESULTS: We identified 510 lipids, of which the top 10 coincided with false discovery threshold of 0.058 in the Training set. From the top 10 lipids, the abundance of diacylglycerols (DAGs) and cholesteryl esters was lower, but that of phosphatidic acid 44:4 and monoacylglycerol (MAG) 16:0 was significantly higher in progressors. Using logistic regression models a multi-marker panel consisting of DAGs, and MAG independently predicted progression. The c-statistic of the multimarker panel added to the base model consisting of eGFR and urine protein-creatinine ratio (UPCR) as compared to that of the base model was 0.92 (95% Confidence Interval [CI]: 0.88-0.97), and 0.83 (95% CI: 0.76-0.90, P<0.01), respectively; an observation which was validated in the Test subset. CONCLUSION: We conclude that a distinct panel of lipids may improve prediction of progression of CKD beyond eGFR and UPCR when added to the base model.
引用
- Afshinnia F, Rajendiran TM, Karnovsky A, et al. Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort. Kidney Int Rep. 2016. PMID: 28451650. doi:10.1016/j.ekir.2016.08.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。